Drugs / BAY1834845
Trials 5
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 14 trials | ||||||
| Phase 1 | NCT05003089 | Jun → Dec 2021 | immune dysregulation, autoimmunity, and autoinflammation | Bayer | Completed | No outcome recorded |
| Phase 1 | NCT03493269 | Apr 2018 → Sep 2020 | psoriasis | Bayer | Completed | No outcome recorded |
| Phase 1 | NCT03244462 | Aug 2017 → Jan 2018 | — | Bayer | Completed | No outcome recorded |
| Phase 1 | NCT03054402 | Feb → Nov 2017 | pelvic inflammatory disease | Bayer | Completed | No outcome recorded |
| Phase 21 trial · 1 missed | ||||||
| Phase 2 | NCT05656911 | Dec 2022 → Jan 2024 | atopic eczema | Bayer | Completed | Missed primary |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 6 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BAY1834845 | “Zabedosertib (BAY1834845) is a potent, selective IRAK4 inhibitor that suppresses markers of local and systemic immune responses.” PMID 40906353 ↗ Sep 2025 |
| Known as | zabedosertib | “Zabedosertib, the interleukin-1 receptor-associated kinase-4 (IRAK4) inhibitor, is in clinical development as an oral therapeutic for immune-mediated inflammatory diseases and...” PMID 40520205 ↗ May 2025 |
| Action | Inhibit | “interleukin-1 receptor-associated kinase-4 (IRAK4) inhibitor” PMID 40520205 ↗ May 2025 |
| Route | Oral | “Increasing Single Oral Doses of BAY1834845” NCT03054402 ↗ |
| Target | IRAK4 | “interleukin-1 receptor-associated kinase-4 (IRAK4) inhibitor” PMID 40520205 ↗ May 2025 |